AI
Sunday, February 03, 2013 9:01:33 AM
February 2013 FDA plays
>>> Link back for January plays
02/10/2013 Celgene Corporation CELG Pomalidomide (NDA)
FDA decision on Pomalidomide for treatment of relapsed and refractory multiple myeloma
02/02/2013 Hemispherx Biopharma, Inc. HEB Ampligen (NDA)
FDA decision on Ampligen for proposed treatment of Chronic Fatigue Syndrome
02/24/2013 Dynavax Technologies Corp DVAX Heplisav (BLA)
FDA decision on Heplisav for immunization against infection caused by all known subtypes of hepatitis B virus in adults 18 through 70 years of age
02/26/2013 Immunogen Inc IMGN Trastuzumab emtansine (BLA)
FDA decision on Trastuzumab emtansine for breast cancer
>>> Link back for January plays
02/10/2013 Celgene Corporation CELG Pomalidomide (NDA)
FDA decision on Pomalidomide for treatment of relapsed and refractory multiple myeloma
02/02/2013 Hemispherx Biopharma, Inc. HEB Ampligen (NDA)
FDA decision on Ampligen for proposed treatment of Chronic Fatigue Syndrome
02/24/2013 Dynavax Technologies Corp DVAX Heplisav (BLA)
FDA decision on Heplisav for immunization against infection caused by all known subtypes of hepatitis B virus in adults 18 through 70 years of age
02/26/2013 Immunogen Inc IMGN Trastuzumab emtansine (BLA)
FDA decision on Trastuzumab emtansine for breast cancer
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
